The Charing Cross Hospital experience with temozolomide in patients with gliomas. (Q48836301)

16 February 2018

title

The Charing Cross Hospital experience with temozolomide in patients with gliomas. (English)

1 reference

16 February 2018

0 references

0 references

4

1 reference

16 February 2018

author name string

E S Newlands

1

1 reference

16 February 2018

S M O'Reilly

2

1 reference

16 February 2018

M G Glaser

3

1 reference

16 February 2018

H Evans

5

1 reference

16 February 2018

C Brock

6

1 reference

16 February 2018

M H Brampton

7

1 reference

16 February 2018

I Colquhoun

8

1 reference

16 February 2018

P Lewis

9

1 reference

16 February 2018

J M Rice-Edwards

10

1 reference

16 February 2018

R D Illingworth

11

1 reference

16 February 2018

P G Richards

12

1 reference

16 February 2018

publication date

1 December 1996

1 reference

16 February 2018

European Journal of Cancer

published in

1 reference

16 February 2018

volume

32A

1 reference

16 February 2018

issue

13

1 reference

16 February 2018

page(s)

2236-2241

1 reference

16 February 2018

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

The role of chemotherapy in the treatment of gliomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Effect of HECNU in malignant supratentorial gliomas--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Accumulation of genetic defects during astrocytoma progression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Grading of astrocytomas. A simple and reproducible method.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

A registration and interpolation procedure for subvoxel matching of serially acquired MR images.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N'-nitro-N-nitrosoguanidine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900258-4

7 January 2021

10.1016/S0959-8049(96)00258-4

Identifiers

DOI

1 reference

16 February 2018

PubMed ID

9038604

1 reference

16 February 2018